Findings from the primary analysis of the phase 3b PATAPSCO study showed that adding durvalumab (Imfinzi) to BCG induction ...

The approval of immunotherapy combinations beginning in 2020 fundamentally altered that calculus, and the April 2025 ...

Preview ASCO 2026 late-breaking cancer trials—from TNBC ADC survival gains to lung, liver, prostate and myeloma readouts ...

NSCLC showed the largest reduction in metastatic progression with GLP-1RAs versus gliptins (HR 0.50), with significant ...

While longer follow-up is needed to determine whether MRD clearance translates into improved clinical outcomes such as ...

Six-year Sequoia data show zanubrutinib in frontline CLL extends PFS far beyond bendamustine‑rituximab, delaying next ...

Genomic assays have become indispensable tools in the management of early-stage invasive breast cancer, helping oncologists ...

In the SEQUOIA trial, the BTK inhibitor zanubrutinib was delivered as a continuous dose in frontline chronic lymphocytic ...

Lipsky,MD, highlights 6-year follow-up data from the phase 3 SEQUOIA trial (NCT03336333) showing that the BTK inhibitor ...

Targeting KMA seeks to spare normal immunoglobulin-producing plasma cells, differentiating from BCMA-directed CAR T ...

Why frontline CLL care shifts to zanubrutinib: simple daily BTK inhibitor therapy cuts infusions, eases pill burden, adds ...

Six-year Sequoia data show zanubrutinib in frontline CLL extends PFS far beyond bendamustine‑rituximab, delaying next ...